Differential association of ezetimibe-simvastatin combination with major adverse cardiovascular events in patients with or without diabetes: a retrospective propensity score-matched cohort study.

Among individual components of MACE, ezetimibe-statin combination therapy was associated with a lower incidence rate of ACS (3.7 and 8.9 per 1000 person-years, incidence rate ratio 0.41, P = 0.025) compared to simvastatin alone in patients with diabetes (Table 3 ), whereas lower incidence rate for CV mortality, coronary revascularization, and ischemic stroke by S + E did not reach statistical significance among diabetes and no diabetes groups.

also in 111,027 other papers